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Skeletal muscle differentiation requires the coordinated activity of transcription factors, histone modifying
enzymes, and ATP-dependent chromatin remodeling enzymes. The type II protein arginine methyltransferase
Prmt5 symmetrically dimethylates histones H3 and H4 and numerous nonchromatin proteins, and prior work
has implicated Prmt5 in transcriptional repression. Here we demonstrate that MyoD-induced muscle differ-
entiation requires Prmt5. One of the first genes activated during differentiation encodes the myogenic regulator
myogenin. Prmt5 and dimethylated H3R8 (histone 3 arginine 8) are localized at the myogenin promoter in
differentiating cells. Modification of H3R8 required Prmt5, and reduction of Prmt5 resulted in the abrogation
of promoter binding by the Brg1 ATPase-associated with the SWI/SNF chromatin remodeling enzymes and all
subsequent events associated with gene activation, including increases in chromatin accessibility and stable
binding by MyoD. Prmt5 and dimethylated H3R8 were also associated with the myogenin promoter in activated
satellite cells isolated from muscle tissue, further demonstrating the physiological relevance of these obser-
vations. The data indicate that Prmt5 facilitates myogenesis because it is required for Brg1-dependent
chromatin remodeling and gene activation at a locus essential for differentiation. We therefore conclude that
a histone modifying enzyme is necessary to permit an ATP-dependent chromatin remodeling enzyme to
function.
Gene expression is a highly regulated process that frequently
requires coordinated function between transcription factors
and chromatin remodeling enzymes. These enzymes are di-
vided into two classes: ATP-dependent remodelers that hydro-
lyze ATP and alter nucleosome structure and histone modifiers
that covalently modify specific histone residues posttransla-
tionally. The activation of skeletal muscle differentiation is
regulated by members of the basic helix-loop-helix family of
tissue-specific transcription factors, including MyoD, Myf5,
Mrf4, and myogenin, as well as by members of the Mef2 family
of transcriptional regulators, which act cooperatively with basic
helix-loop-helix proteins (8, 34, 43). Numerous chromatin re-
modeling enzymes have been shown to both positively and
negatively affect myogenic gene expression. These include his-
tone acetyl transferases; types I, II; and III histone deacety-
lases; histone lysine methyltransferases; and members of the
SWI/SNF family of ATP-dependent remodeling enzymes (17,
47, 50). The relationships between the different classes of chro-
matin remodeling enzymes during myogenesis have been
largely unexplored.
The protein arginine methyltransferases (PRMTs) are an
additional class of enzymes that can be linked to histone mod-
ification and gene regulation during skeletal muscle differen-
tiation. This family has 9 members (Prmt1 to Prmt9), six of
which have been shown to generate asymmetric (type I) or
symmetric (type II) dimethylarginine and to affect a range of
cellular processes through arginine methylation of substrate
proteins (6, 50). Of particular note, the Prmt4 enzyme, also
called Carm1, has been linked to skeletal muscle differentia-
tion and to control of estrogen-mediated gene activation via
methylation of histones H3 and H4 (5, 9, 12, 53). Prmt4 func-
tions at estrogen-induced promoters as part of a multiprotein
complex that also contains the Brg1 ATPase of SWI/SNF chro-
matin remodeling complexes (53). Another family member,
Prmt5, has also been isolated as part of an enzymatic complex
containing Brg1, though in this case the complex is associated
with transcriptional repression of genes involved in growth
control and tumor suppression (41, 42). Other studies indi-
cated that Prmt5 acts as a repressor of cyclin E (21, 44). Prmt5
was also shown to associate with and methylate the elongation
factor Spt5, which decreased this protein’s affinity for RNA
polymerase II and impeded transcriptional elongation (30).
Thus, Prmt5 negatively affects gene expression via symmetric
arginine methylation of both histones and components of the
transcriptional machinery. Prompted by association between
Prmt5 and Brg1 as well as by the fact that Prmt4 is involved in
the transcriptional regulation of myogenic genes, we sought to
determine whether Prmt5 contributes to skeletal muscle dif-
ferentiation.
Previous work described NIH 3T3-based cell lines that con-
stitutively express a Prmt5 antisense vector and thereby cause
a significant reduction in Prmt5 mRNA and protein levels (41).
Ectopic expression of MyoD in fibroblast cells induces the
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myogenic differentiation program (13); this system has been
extensively utilized to examine the mechanisms of skeletal
muscle gene regulation for nearly 20 years (50). Using this
system, we determined that cells containing reduced levels of
Prmt5 failed to activate myogenic gene expression upon intro-
duction of MyoD. Detailed examination of the events leading
to activation of the myogenin locus, the production of which is
necessary for the activation of myogenic late genes that encode
structural and functional skeletal muscle proteins, determined
that Prmt5 dependent dimethylation of histone 3 arginine 8
(H3R8) was required for the interaction of the SWI/SNF
ATPase Brg1, for chromatin remodeling of the locus, and for
all subsequent events leading to gene activation. We also
present evidence that Prmt5 interacts with the myogenin pro-
moter in activated satellite cells isolated from adult skeletal
muscle tissue, which further supports the conclusion that
Prmt5 functions in myogenic gene activation and is necessary
for the induction of skeletal muscle differentiation. Thus, we
have determined that a histone methyltransferase is necessary
for the function of an ATP-dependent chromatin remodeling
enzyme during tissue differentiation.
MATERIALS AND METHODS
Cell culture. Cells were maintained in Dulbecco’s modified Eagle’s medium
supplemented with 10% calf serum and 2 mM L-glutamine. Prmt5 antisense lines
were maintained in the presence of 2.5 g/ml puromycin, since the antisense
vector encodes a puromycin resistance gene (41). Cells were differentiated as
previously described (15, 18) except that the pBABE-MyoD retroviral construct
was modified to contain a blasticidin resistance gene instead of one for puromy-
cin. Briefly, cycling cells were split so that they would be 75% confluent 24 h later.
At that time, retroviral infection with the MyoD encoding retrovirus was per-
formed for 30 h. Subsequently, differentiation medium (Dulbecco’s modified
Eagle’s medium containing 2% horse serum, 2 mM L-glutamine, 5 g/ml blas-
ticidin, 2 g/ml puromycin, and 10 g/ml insulin) was added to the cells, and
samples were collected at the indicated times. Control samples from both NIH
3T3 cells and antisense lines were mock infected and subjected to the differen-
tiation protocol and are designated “mock differentiated.”
B22 cells expressing a Flag-tagged, dominant negative version of the SWI/SNF
ATPase subunit BRG1 in the absence of tetracycline were described previously
(14). Cycling cells were grown in the presence or absence of tetracycline for 3
days, were split to be 50 to 60% confluent 24 h later, and then were subjected to
the differentiation protocol described above.
mRNA analysis. RNA was isolated from mock- or MyoD-differentiated sam-
ples using Trizol (Invitrogen) and reverse transcribed as previously described
(16). The cDNA was amplified using a QIAGEN HotStarTaq Master Mix kit
(QIAGEN) containing 0.1 g of specific primers and SYBR green. Reverse
transcription-PCR (RT-PCR) and real-time PCR were performed using proce-
dures and primers described previously (10, 39, 51). The dystrophin primer set
was 5-AAG TTT GGA AAG CAA CAC ATA-3 and 5-GTT CAG GGC ATG
AAC TCT TG-3. Prmt5 primers were 5-GAT GGC GGC GAT GGC A-3 and
5-CTG TGT GTG TAG TCG G-3. All data sets are the average  standard
deviation of three or more independent experiments.
Fluorescence-activated cell sorting (FACS). Cells were differentiated or mock
differentiated as stated above and fixed as previously described (29). Propidium
iodide incorporation was measured by flow cytometry to determine the percent-
age of cells in each phase of the cell cycle.
Protein extracts, Western analysis, and antibodies. Whole-cell extracts were
generated as previously described (18, 20). For Western analysis, 100 g of each
extract was used for sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) followed by transfer to nitrocellulose. Coimmunoprecipitation
procedures were previously described (16, 39). Antibodies used for chromatin
immunoprecipitation (ChIP) included polyclonal rabbit antisera against Prmt5
and dimethylated H3R8 (41, 42), Brg1 (14), Flag epitope, and MyoD (16).
Western analysis also made use of commercial antibodies against Prmt5/JBP1/
Skb1Hs (catalog no. 611538; BD Biosciences) and MyoD (catalog no. 554130
and 554099; BD Biosciences).
ChIP. ChIPs were performed by modifying the Upstate protocol as previously
described (46). Cultured cells or nuclei isolated from tissues (see below) were
cross-linked in 1% formaldehyde and lysed in buffer containing 1% SDS, 10 mM
EDTA, 50 mM Tris-HCl, pH 8.1. Samples were incubated on ice, and the DNA
was sheared by sonication to obtain an average length of 500 bp. A total of 100
g of sonicated DNA was diluted 10-fold in immunoprecipitation buffer (0.01%
SDS, 1.1% triton-X100, 1.2 mM EDTA, 16.7 mM Tris, pH 8.1, 167 mM NaCl)
containing protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 1 g/ml
aprotinin, 1 g/ml pepstatin A) and precleared with a 50% slurry of protein A
beads (Amersham) at 4°C for at least 1 h. Cleared lysates were incubated with
antibodies described above at 4°C for 4 h or overnight. Protein A beads were
added to precipitate immune complexes from the cell lysates and incubated for
1 h at 4°C. Beads were collected by centrifugation and then washed as previously
described (46), and immune complexes were eluted from the beads using 1%
SDS. Cross-links were reversed, and DNA was purified by a Qiaquick PCR
purification kit (QIAGEN). Analysis of immunoprecipitated DNA was per-
formed by PCR amplification (16) or by quantitative PCR (QPCR) using a
Quantitect SYBR Green PCR kit. Primers were described previously (16, 39).
Chromatin reimmunoprecipitation (re-ChIP) experiments were performed as
previously described (36, 39). QPCR data are the average  standard deviation
of three independent experiments.
REAA. Restriction enzyme accessibility assay (REAA) and detection by a
modified version of ligation-mediated PCR were described previously (16, 39).
Data are the average  standard deviation of three independent experiments.
Isolation of satellite cells and myofibers from mouse skeletal muscle. Skeletal
muscle was dissected from the upper hind limbs of 4- to 6-week-old C57/BL6
mice and minced to approximately 1 mm3. Tissues were then digested using 87.5
U/ml collagenase type II (Invitrogen) in phosphate-buffered saline supplemented
with 1 mM CaCl2 and incubated at 37°C for 1 h with agitation (3, 11). Satellite
cells were separated from mature myofibers by filtration with a cell strainer
(70um; Becton Dickinson catalog no. 352350) (40). Flowthrough material was
enriched for satellite cells, while material that did not pass through the filter was
enriched for myofibers. Aliquots were taken for isolation of RNA as described
above. Satellite and myofiber preparations were kept on ice throughout the
process. The separated fractions were separately pelleted by centrifugation and
resuspended in 7 volumes of lysis buffer (10 mM HEPES-KOH (pH 7.3), 10 mM
KCl, 5 mM MgCl2, 0.5 mM dithiothreitol, 0.2 mM phenylmethylsulfonyl fluoride,
3 g/ml cytochalasin B, 10 g/ml leupeptin). Samples were homogenized and
dounced using pestle A to release nuclei, and then samples were incubated on ice
for 30 min. Nuclei release and integrity were checked under a light microscope
with Hoechst 33258 dye, and the samples were then centrifuged to remove cell
debris. Nuclei were resuspended in 2.5 volumes of 10 STM buffer (5 mM MgCl2,
10 mM triethanolamine pH 7.5, 5 mM MgCl2, 10% sucrose, 10 g/ml leupeptin)
and subsequently 2 volumes of 2 M sucrose–10 mM Tris-HCl–5 mM MgCl2. In
an ultracentrifuge tube (Beckman catalog no. 344057), 750 l of the 2 M su-
crose–10 mM Tris HCl–5 mM MgCl2 mixture was aliquoted and overlaid with
the nuclei mixture described above. Samples were ultracentrifuged at 116,140 
g for 1 h. The supernatant was aspirated and discarded, and the pellet was
resuspended in 500 l of lysis buffer containing 0.1% NP-40. Following cross-
linking with 2% formaldehyde at room temperature, nuclei were centrifuged at
13,500  g, pellets were frozen in liquid nitrogen, and samples were stored at
80°C or immediately thawed, resuspended in lysis buffer described above, and
sonicated.
RESULTS
Transcription of skeletal muscle genes is significantly im-
paired in cells with reduced levels of Prmt5. Cooperation be-
tween myogenic transcription factors and chromatin remodel-
ing enzymes is needed to properly regulate the transcription of
muscle-specific genes. To address the function of the Prmt5
arginine methyltransferase in skeletal muscle differentiation,
we utilized two independently derived NIH 3T3 cell lines that
express a Prmt5 antisense vector. These cell lines were previ-
ously shown to have significantly decreased levels of this pro-
tein and its corresponding mRNA (41).
In vitro skeletal muscle differentiation was initiated by in-
fection of both the control and antisense lines (c15 and c12
cells) with a retrovirus encoding MyoD (15, 38) for 30 h. After
VOL. 27, 2007 Prmt5 ACTIVATES MYOGENIC GENE EXPRESSION 385
infection, low-serum differentiation medium was added to the
cells, and the cells were allowed to undergo differentiation for
36 h. Control samples that were mock infected were also
placed in differentiation medium and are referred to as mock
differentiated. Western analysis was performed to demonstrate
that the antisense vector present in these two clones reduced
the amount of Prmt5 in both mock- and MyoD-differentiated
c15 and c12 cells (Fig. 1A).
RT-PCR was performed to determine if the reduction of
Prmt5 had an effect on the transcription of myogenic target
genes. As shown in Fig. 1B, expression of MyoD mRNA was
comparable in each cell line, indicating that each cell line was
infected by the retrovirus and expressed equivalent levels of
MyoD. As expected, both the early muscle marker myogenin
and the late genes desmin and skeletal alpha actin were in-
duced upon differentiation with MyoD in the control cells. In
contrast, in MyoD-differentiated Prmt5 antisense lines, the
expression of all three marker genes was significantly reduced.
Quantitative real-time PCR was used to more precisely mea-
sure the differences in transcript levels (Fig. 1C). Impaired
gene activation of early and late muscle-specific transcripts
suggests a role for Prmt5 in the activation of myogenic tran-
scription during the differentiation process.
In order to initiate the process of skeletal muscle differen-
tiation, MyoD promotes cell cycle arrest, which involves the
induction of cyclin-dependent kinase inhibitors such as p21
and cell cycle regulators like retinoblastoma protein (32, 54).
As a consequence, the activity of cyclins and cyclin-dependent
kinases is downregulated, and cell cycle arrest is achieved. To
eliminate the possibility that defects seen in myogenic gene
expression upon reduction of Prmt5 levels stem from aberrant
cell cycle arrest, we performed FACS analysis following pro-
pidium iodide incorporation to determine whether the cells
were arresting properly (Table 1). The percentage of cells in S
phase did not differ between the control and antisense cell lines
under any of the conditions evaluated. Cycling cell populations
contained approximately 30% of cells in S phase. In mock- or
MyoD-differentiated cells, the percentage of cells in S phase
was 12 to 14% (Table 1), which is consistent with the level of
cell cycle withdrawal that can be achieved with immortalized
fibroblasts under these conditions (18, 45). These data indicate
that the control and both Prmt5 antisense lines withdrew from
the cell cycle upon differentiation. RT-PCR analysis indicated
that p21, cyclin D3, p16, and retinoblastoma protein mRNAs
were upregulated equivalently in each of the cell lines upon
differentiation with MyoD (data not shown), further corrobo-
rating these findings. Thus, the reduction in myogenic gene
expression observed upon reduction of Prmt5 levels was not
due to a failure of the cells to undergo cell cycle arrest. These
FIG. 1. Prmt5 is required for skeletal muscle differentiation. NIH 3T3 cells and two independently derived NIH 3T3 lines expressing an
antisense vector against Prmt5 (c15 and c12 cells) were mock-differentiated or differentiated by ectopic expression of MyoD. (A) Western blots
show that protein levels of Prmt5 were significantly reduced in differentiated and mock-differentiated antisense lines compared to levels in the
parental NIH 3T3 cells. Cells were differentiated as described in Materials and Methods for 36 h prior to sample collection. (B) Expression of
myogenic target genes myogenin, desmin, and skeletal alpha-actin (Sk. -actin) and ectopic expression of MyoD were monitored by RT-PCR in
mock- and MyoD-differentiated cells collected 36 h postdifferentiation. (C) Quantification of muscle-specific gene expression by quantitative
real-time PCR confirms that early and late differentiation markers are significantly decreased in cells containing reduced levels of Prmt5. PI3K,
phosphatidylinositol 3-kinase.
TABLE 1. Results of FACS analysis
Cell line




NIH 3T3 29.7  1.6 13.0  3.0 13.6  2.1
c15 27.4b 10.8  4.5 11.8  2.2
c12 28.3b 12.4  4.2 11.8  0.4
a Results are expressed as the average  standard deviation of three experi-
ments.
b Average of two experiments.
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data indicate that Prmt5 is not needed for cell cycle arrest
under the conditions utilized for these experiments. Further-
more, Prmt5 is not required for all MyoD-induced gene ex-
pression, since the cell cycle regulators upregulated during
MyoD-mediated differentiation were upregulated normally
when Prmt5 levels were reduced.
The requirement for Prmt5 during MyoD-induced differen-
tiation suggests that Prmt5 may physically associate with MyoD
and other regulators of differentiation. Coimmunoprecipita-
tion experiments revealed that endogenous Prmt5 was associ-
ated with MyoD in differentiating cells (Fig. 2). As expected,
no interactions were observed in mock-differentiated cells or in
Prmt5 antisense cells. Additional experiments showed that en-
dogenous Prmt5 was associated with endogenous Brg1 (Fig. 2).
This association was not dependent upon differentiation, con-
sistent with previous reports demonstrating that a subset of
Brg1 containing SWI/SNF chromatin remodeling enzymes is
associated with Prmt5 in tumor-derived cell lines (41, 42).
Prmt5 binding and H3R8 dimethylation at the myogenin
promoter are required for binding of Brg1 and MyoD. We
wished to determine if Prmt5 was directly influencing the ex-
pression of the myogenin gene promoter by directly interacting
with its regulatory regions. We examined the myogenin pro-
moter because transcriptional activation at this locus is neces-
sary for the subsequent expression of late marker genes, such
as desmin and skeletal alpha-actin, and for terminal differen-
tiation. ChIP for Prmt5 was performed in mock- and MyoD-
differentiated NIH 3T3 and Prmt5 antisense lines (Fig. 3A and
B). In the NIH 3T3 cells, binding of Prmt5 to the myogenin
promoter required MyoD-induced differentiation. H3R8 is a
known substrate for Prmt5 (41, 42). Dimethylation of H3R8 at
the myogenin promoter was enriched upon differentiation. As
FIG. 2. Prmt5 coimmunoprecipitates with Brg1 and MyoD. Mock-differentiated cells, nondifferentiated (time zero [T0]) MyoD-infected cells,
or MyoD-infected cells that were exposed to differentiation conditions for 36 h were harvested and used to perform coimmunoprecipitation
experiments with the indicated antibodies. (A) Indicated proteins were detected by Western blotting using 10% of the input sample. (B) Whole-cell
extracts from mock and differentiated samples were coimmunoprecipitated with Prmt5 antibody (catalog no. 611538; BD Biosciences) or purified
immunoglobulin G (IgG). Immunoprecipitated material was run on SDS-PAGE gels, transferred to a membrane, and probed for the presence of
Brg1, MyoD, and Prmt5. (C) As a control, the experiment in panel B was repeated using the c15 Prmt5 antisense line mock differentiated or MyoD
differentiated for 36 h. Each Western blot panel contains data from the same blot; intervening samples were removed for clarity. (D) Coimmu-
noprecipitations were performed using Brg1 antisera and probed for Prmt5 and Brg1. (E) Coimmunoprecipitations were performed using MyoD
antisera and probed for the presence of Prmt5 and MyoD. WB, Western blot; PI3K, phosphatidylinositol 3-kinase.
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expected, Prmt5 binding was significantly reduced in the
antisense lines and was comparable to binding seen in mock-
differentiated cells. Similarly, in the antisense lines, dimethy-
lation of H3R8 was reduced to the level observed in mock-
differentiated samples, indicating that dimethylation of H3R8
at the myogenin promoter required Prmt5.
To further investigate the interaction of Prmt5 with the
myogenin promoter, ChIPs were performed over a time course
of differentiation. Both Prmt5 and dimethylated H3R8 were
detected at the time when differentiation medium was first
added (time zero), and the interaction of these proteins was
observed throughout the time course (Fig. 3C). These interac-
tions precede the activation of myogenin expression (16), sug-
gesting that the Prmt5 methyltransferase contributes to the
initial promoter reorganization that promotes myogenin ex-
pression. Curiously, though the levels of dimethylated H3R8 at
the myogenin promoter were relatively constant during the
differentiation protocol, a reproducible increase in amount of
Prmt5 present at the promoter was observed between 0 and
12 h postdifferentiation (Fig. 3C). The significance of this ob-
servation, if any, is not known.
Prior work showed that induction of myogenin transcription
required the binding and activity of Brg1, an ATPase that is the
catalytic subunit of some of the SWI/SNF chromatin remod-
eling enzymes (15). To ascertain whether a reduction in Prmt5
affected Brg1 binding to the myogenin promoter, additional
ChIPs were performed. These experiments showed that in cells
with reduced levels of Prmt5, recruitment of Brg1 at the myo-
genin promoter was diminished to the level of binding seen in
mock-differentiated cells (Fig. 4A and B). Control Western
blots showed that the lack of Brg1 binding to the myogenin
locus was not due to changes in Brg1 levels in the Prmt5
antisense cells (Fig. 4C). Thus, Prmt5 binding and dimethyla-
tion of H3R8 are prerequisites for Brg1 binding. The lack of
Brg1 at the myogenin promoter implies a lack of chromatin
remodeling at this locus. An REAA allowed us to detect ac-
cessibility changes in the chromatin at the myogenin locus in
response to induction of differentiation by MyoD in the pres-
ence of normal and reduced levels of Prmt5. When mock-
differentiated, none of the cell lines displayed significant en-
zyme accessibility at the myogenin locus (Fig. 4D). Upon
differentiation there was an expected increase in accessibility in
the NIH 3T3 cells, but little or no accessibility was observed in
the Prmt5 antisense lines. These findings reiterate the require-
ment for Brg1 to alter myogenin promoter structure in a man-
ner that permits restriction enzyme accessibility and indicate
that the presence of Prmt5 and dimethylated H3R8 is insuffi-
cient to cause such structural changes at the myogenin locus.
Previous work has implicated the Pbx/Meis homeodomain
factors as playing an important role during the induction of
myogenin transcription by providing a mechanism to initially
target MyoD to the locus (7, 28). Further studies showed that
FIG. 3. Prmt5 binds to the myogenin promoter and dimethylates H3R8. ChIPs were performed using antibodies against Prmt5 and dimethy-
lated (diMe) H3R8 in mock- and MyoD-differentiated NIH 3T3 and Prmt5 antisense cell lines. (A) ChIPs demonstrate that binding of Prmt5 and
dimethylated H3R8 at the myogenin promoter in differentiated cells is significantly reduced in the antisense lines. Amplification of the coding
region of elongation factor EF1-alpha was performed as a negative control. (B) Quantification of Prmt5 binding and H3R8 dimethylation at the
myogenin promoter was performed by QPCR. (C) Time course of Prmt5 and dimethylated H3R8 association with the myogenin promoter. QPCR
analysis of binding in differentiated cells at the indicated times is shown. Values are expressed relative to the values obtained at time zero, which
was set at 1.
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Brg1-mediated chromatin remodeling at the myogenin pro-
moter subsequently permits stable binding of MyoD to its
consensus binding sites upstream and downstream of the Pbx/
Meis site (16). Since Brg1 did not bind to or remodel chroma-
tin at the myogenin promoter in Prmt5 antisense cell lines, we
would predict that stable binding of MyoD would also not be
observed in these cells. As expected, an additional conse-
quence of decreased Brg1 interactions in the antisense lines
was that binding of MyoD was reduced to background levels
(Fig. 4A and B). In summary, the reduction in Prmt5 levels
resulted in a failure to activate myogenin expression because
neither Prmt5 nor Brg1 interacted with the promoter. Thus,
subsequent events such as histone methylation, ATP-depen-
dent chromatin remodeling, and MyoD binding did not occur.
To further probe the molecular events occurring at the myo-
genin locus, we assessed whether binding of Prmt5 and di-
methylation of H3R8 required functional Brg1. We previously
described and characterized tetracycline-suppressible cell lines
that in the absence of tetracycline (Tet) express a Flag-tagged,
ATPase-deficient, dominant negative Brg1 protein (14, 15) and
showed that expression of dominant negative Brg1 blocks ac-
tivation of myogenic early and late genes because chromatin
remodeling at each inducible locus is blocked (15, 16, 39).
Upon differentiation with MyoD, Prmt5 was able to bind to the
myogenin promoter in cells expressing functional Brg1 (with
Tet) as well as in cells expressing the dominant negative ver-
sion of Brg1 (without Tet) (Fig. 5A). Dimethylation of H3R8
was also enriched at the promoter, regardless of the functional
status of Brg1 (Fig. 5A). Control Western blots demonstrated
that Prmt5 protein levels were unaffected by the expression of
dominant negative Brg1, and, as previously documented, ex-
pression of dominant negative Brg1 did not alter the overall
levels of Brg1 in the cells (Fig. 5B) (16). Additional mRNA
analyses indicated that MyoD was equivalently expressed in
cells expressing or lacking dominant negative Brg1 and that the
expression of dominant negative Brg1 inhibited subsequent
myogenic gene expression (Fig. 5C and data not shown). We
conclude that chromatin remodeling by Brg1 is not required to
facilitate the binding of Prmt5 at the myogenin promoter.
Thus, Prmt5 binding is required for the binding of Brg1, but
Brg1 function is not needed for the binding of Prmt5.
Prmt5 and dimethylated H3R8 are present at the myogenin
locus of satellite cells in vivo. To determine whether Prmt5
binds to the myogenin promoter in vivo, we isolated hind limb
muscle from 4- to 5-week-old BL6 mice and separated satellite
cells and myofibers (see Materials and Methods). Satellite cells
are quiescent muscle progenitor cells located in the basal lam-
ina of mature muscle fibers (33, 48). Upon activation, they
express myogenic regulatory factors and initiate the differen-
tiation program by proliferating and fusing with existing myo-
fibers or fusing to form new myofibers (reviewed in references
19 and 25). Investigation of the molecular roles of transcrip-
tional regulators and chromatin remodeling enzymes during
myogenic gene activation in these cells has been limited by the
difficulties associated with isolation and analysis of these cell
populations.
The separation protocol utilized results in a satellite cell
pool that contains both quiescent and activated cells. To eval-
uate whether the purification scheme adequately separated
satellite cells from myofibers, quantitative PCR was performed
to examine the expression of satellite cell and myofiber marker
genes. Pax3 is a transcription factor that is a member of the
paired box/homeodomain family and is expressed in satellite
cells (10). Pax3 is highly expressed in satellite cells compared to
FIG. 4. Brg1 and MyoD binding at the myogenin promoter require Prmt5. (A) ChIPs were performed using antibodies against Brg1 and MyoD
in mock- and MyoD-differentiated cell lines harvested 36 h postdifferentiation, and the myogenin promoter and elongation factor EF1-alpha coding
region (input control) were PCR amplified. Data in panel A and Fig. 3A were from the same experiment; thus, the input control bands are the
same for both panels. (B) Brg1 and MyoD binding were quantified by QPCR. (C) Western blot showing that Brg1 and MyoD protein levels were
unaffected by the reduction in Prmt5 protein levels. (D) An REAA was performed to evaluate the accessibility of a Pvu II site at 320 relative
to the myogenin mRNA start site. Chromatin accessibility was dependent upon Prmt5 expression.
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mature myofibers or the negative control liver tissue, indicating
that this fraction is enriched for satellite cells while the myo-
fiber preparation contains few if any satellite cells (Fig. 6A).
Since the satellite cell fraction contains both quiescent and
activated satellite cells, both satellite cell and myofiber frac-
tions displayed expression of MyoD and myogenin, as ex-
pected. Expression of the late skeletal muscle marker dystro-
phin was seen only in the myofiber fraction, establishing that
the satellite cell fraction was not contaminated with myofibers
(Fig. 6A).
We then isolated nuclei from these separated tissue samples
and performed ChIP experiments to assess factor interactions
at the myogenin locus. Prmt5 was highly enriched at the myo-
genin promoter in satellite cells, but this enrichment was sig-
nificantly reduced in the myofibers (Fig. 6B). H3R8 dimethy-
lation also was highly enriched at the myogenin promoter in
satellite cells while enhanced to a much lesser extent at the
myogenin promoter in myofibers, which is consistent with the
reduced binding of Prmt5 that was observed. Comparable lev-
els of Prmt5 were expressed in both tissue samples (Fig. 6C).
Since the satellite cell population contains both quiescent
and activated cells, we could not definitively conclude that
Prmt5 association with the myogenin promoter was related to
the activation of gene expression in these cells. To better ad-
dress this question, we asked whether Prmt5 and MyoD could
be colocalized to the myogenin promoter. Since only activated
satellite cells express MyoD, the simultaneous presence of
MyoD and Prmt5 would indicate that Prmt5 was present at
the myogenin locus in cells that were actively expressing
myogenin. Re-ChIP experiments were performed in which
chromatin from satellite cell nuclei immunoprecipitated
with Prmt5 antibodies was subsequently immunoprecipi-
tated with MyoD antibodies. The results show that Prmt5
and MyoD are present together at the myogenin locus in
activated satellite cells (Fig. 6D).
Collectively, these results indicate that the Prmt5 arginine
methyltransferase is required for MyoD-mediated differentia-
tion. Examination of one of the early myogenic target genes
shows that Prmt5 binds to the myogenin promoter and di-
methylates H3R8. Prmt5 binding was required for association
of the Brg1 chromatin remodeling enzyme with the promoter
and for all subsequent events that occur during the activation
of myogenin expression. Thus, cells containing reduced levels
of Prmt5 failed to activate myogenin and, due to the absence of
myogenin, failed to activate myogenic late genes, leading to the
observed block in differentiation. The corecruitment of Prmt5
and MyoD to the myogenin locus in primary satellite cells
corroborates a role for Prmt5 in myogenic differentiation in
vivo. The findings presented here provide evidence for an
important physiological role for Prmt5 during the induction
of skeletal muscle differentiation because it facilitates ATP-
dependent chromatin remodeling at myogenic loci, which then
leads to gene expression.
DISCUSSION
Prmt5 is necessary for the activation of myogenin expres-
sion and myogenesis. The results indicate that the protein
methyltransferase Prmt5 is required for MyoD-mediated skel-
etal muscle differentiation. Prmt5 localizes to the myogenin
promoter, a MyoD inducible gene whose expression mediates
terminal differentiation (24, 27, 37). In both cell culture and
satellite cells isolated from muscle tissue, the presence of
Prmt5 at the myogenin promoter is coincident with the pres-
ence of dimethylated H3R8, a known substrate for Prmt5 (41).
Manipulated cells expressing low levels of Prmt5 were unable
FIG. 5. Prmt5 is able to bind to and dimethylate H3R8 at the myogenin promoter in the absence of functional Brg1. ChIPs were performed
36 h postdifferentiation in a cell line containing a Tet-suppressible vector expressing a Flag-tagged, ATPase-deficient, dominant negative Brg1.
(A) QPCR shows binding of Prmt5 and dimethylated H3R8 at the myogenin promoter in the presence ( Tet) and absence (Tet) of functional
Brg1. (B) Protein levels of Brg1, Prmt5, and the Flag-tagged dominant negative mutant Brg1 were evaluated by Western blotting. Expression of
Flag in samples without Tet indicates expression of dominant negative Brg1. (C) QPCR evaluation of MyoD mRNA, to demonstrate that
differentiated cells expressed MyoD, and myogenin, to demonstrate that MyoD-dependent gene expression was inhibited by dominant negative
Brg1. PI3K, phosphatidylinositol 3-kinase.
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to activate the expression of myogenin or other muscle-specific
genes, and the lack of activation correlated with the lack of
Prmt5 and dimethylated H3R8 at the myogenin locus. More-
over, both Prmt5 and dimethylated H3R8 were present at the
myogenin locus prior to, at the onset of, and following myo-
genin expression. Finally, re-ChIP experiments from satellite
cell nuclei indicate the presence of both MyoD and Prmt5 at
the myogenin promoter in primary tissue. The satellite cell
pool contains both quiescent cells as well as activated cells that
have initiated differentiation. Since only the activated cells
express MyoD, the re-ChIP experiment places Prmt5 on the
myogenin promoter in primary cells that are actively express-
ing myogenin and are in the process of differentiating. The
results support the conclusion that Prmt5 promotes gene acti-
vation during skeletal muscle differentiation.
There are two previous reports suggesting that Prmt5 pro-
motes reporter gene activation; all other studies suggest that
Prmt5 functions in transcriptional repression. In one study,
dose-dependent reduction of Prmt5 by RNA interference
methods resulted in corresponding decreases in NFAT- and
interleukin-2 (IL-2)-driven promoter activity and in IL-2 se-
cretion, suggesting that Prmt5 promotes IL-2 expression (44).
In a different report, Prmt5 was purified in a multiprotein
complex with p44, an androgen receptor (AR) interacting pro-
tein that enhances AR-dependent transcription. Prmt5 acted
synergistically with p44 to mediate AR-dependent reporter
FIG. 6. Prmt5 binds to and dimethylates H3R8 at the myogenin promoter in muscle satellite cells. (A) The separation and purification of
satellite cells and myofibers were monitored by QPCR of marker gene mRNAs. (B) ChIP analysis using nuclei obtained from muscle satellite cells
and myofibers indicates that Prmt5 binding and dimethylated H3R8 were present at the myogenin promoter in satellite cells and at reduced levels
in myofibers. (C) Transcript levels of Prmt5 in both cell types were quantified by QPCR. (D) Re-ChIP analysis quantified by QPCR. Materials
immunoprecipitated with Prmt5 antibodies were subsequently immunoprecipitated with MyoD antibodies. QPCR data are the average  standard
deviation of three independent experiments.
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gene expression. However, activation by Prmt5 in this system
did not require its methyltransferase function; thus, the mech-
anism by which Prmt5-activated transcription occurred was not
clear (26). In contrast, Prmt5 involvement in gene repression is
better understood. Interestingly, multiple mechanisms appear
to be involved. Prmt5 can methylate the elongation factor,
Spt5, which decreases its affinity for polymerase II (Pol II) and
impedes transcription elongation (30). In contrast, Prmt5 di-
rectly binds to regulatory sequences controlling expression of
cyclin E, the tumor suppressors NM23 and ST7, and the c-myc
target gene, CAD, and methyltransferase function was re-
quired for repression where examined (21, 41, 42). Microarray
and confirmatory RT-PCR experiments identified additional
Prmt5 target genes also involved in cell growth control (41).
Dimethylation of H3R8 at promoter sequences was associated
with repression of the genes examined, and purification of
Prmt5 as part of a multienzyme complex with histone deacety-
lase 2 and the SWI/SNF ATPase Brg1 (42) suggests mecha-
nisms by which nucleosomes on gene regulatory sequences can
be altered and/or repositioned and by which histones can be
dimethylated and deacetylated in a manner that leads to tran-
scriptional repression.
Prmt5 also functions in complexes with RNA Pol II and the
Pol II-associated phosphatase FCP1 and with several cytosolic
proteins that together with Prmt5 promote snRNP assembly
(2, 4, 35). Thus, it is established that Prmt5 can function in
multiple capacities in multiple complexes, likely through its
protein methylase activity, to regulate disparate cellular pro-
cesses. Our results suggest that Prmt5 may also be a compo-
nent of one or more additional complexes that function as
coactivators of gene expression.
Interestingly, while Prmt5 was required for myogenin ex-
pression as well as for the expression of several skeletal mus-
cle-specific late genes, cell cycle regulators that are upregu-
lated during MyoD-mediated differentiation to promote cell
cycle withdrawal were induced normally in the Prmt5 antisense
cells lines. This result indicates that Prmt5 is not required for
the activation of every MyoD target gene and is reminiscent of
previous studies that showed that the SWI/SNF chromatin
remodeling enzymes were required for activation of myogenin
and many skeletal muscle-specific late genes but not for the
activation of cell cycle regulators (18, 45). cDNA expression
array analysis ultimately revealed that while almost all of the
genes induced by MyoD in this culture system showed at least
a modest dependence on the presence of functional SWI/SNF
enzymes, only about one-third of these genes were highly de-
pendent on functional SWI/SNF enzymes (16). We predict that
the set of genes that showed the greatest requirement for
SWI/SNF enzymes will also be highly dependent upon Prmt5;
GeneChip analyses will be required to definitively address this
issue.
Prmt5 function facilitates ATP-dependent chromatin re-
modeling in the cascade of events leading to myogenin expres-
sion. The observation that Prmt5 is required for the binding
and function of the Brg1 ATP-dependent chromatin remod-
eler indicates that the histone methyltransferase is required for
ATP-dependent chromatin remodeling to occur. Though there
are reports of specifically modified histones serving as recog-
nition sites for the interaction of specific subunits of ATP-
dependent chromatin remodeling enzymes with chromatin (1,
22, 23, 31, 52), we believe this is the first demonstration that a
specific histone modification enzyme is required for an ATP-
dependent chromatin remodeling enzyme to modify chromatin
structure and activate gene expression from an endogenous
locus.
A number of studies have examined the factors involved in
and the order of events that lead to activation of the myogenin
locus (7, 16, 49). Prior studies showed the homeodomain factor
Pbx constitutively interacting with the myogenin promoter and
providing a mechanism to initially target MyoD to the pro-
moter. This led to promoter-specific histone acetylation, fol-
lowed by binding of the Brg1 ATPase of SWI/SNF chromatin
remodeling enzymes. Subsequent steps, including increased
chromatin accessibility, stable binding of MyoD and Mef2 to
the promoter, and activation of myogenin transcription, were
absolutely dependent upon Brg1 function. The kinetics of his-
tone acetylation and Brg1 binding, coupled with protein-pro-
tein interactions between endogenous Brg1 and endogenous
Pbx at the initiation of the differentiation process, supported
the idea that chromatin modifying enzymes were targeted to
the promoter via the MyoD/Pbx/Meis complex to permit his-
tone modifications and ATP-dependent chromatin remodel-
ing, thereby enabling stable occupancy by transcription factors
required for myogenin transcription. The dependency of Brg1
binding on the presence of Prmt5 places Prmt5 function early
in the activation process, coincident with or preceding Brg1
interaction with the promoter. The timing of Prmt5 function
and the observed physical associations between Prmt5, MyoD,
and Brg1 suggest a similar mechanism of remodeling enzyme
targeting to the myogenin promoter.
The observation that Prmt5 is required for the association of
Brg1 with the myogenin promoter and its subsequent chroma-
tin remodeling functions suggests that either the physical pres-
ence of Prmt5 at the myogenin promoter and/or the dimethy-
lation of H3R8 at the promoter facilitates Brg1 binding.
Histone acetylation also precedes Brg1 interaction at the myo-
genin promoter (16), and both in vivo and in vitro data indicate
that the bromodomain present in Brg1 interacts with acety-
lated histones and that SWI/SNF complex function can be
facilitated by histone acetylation (1, 22, 23). We speculate that
Brg1 has a higher affinity for chromatin that contains H3R8
dimethylated by Prmt5 and that H3R8 dimethylation might
combine with histone acetylation to create a more permissive
substrate for Brg1-dependent chromatin remodeling.
Functional interplay between different methyltransferases
during myogenesis. A distinct protein methyltransferase,
Prmt4/Carm1, was previously shown to contribute to myogen-
esis (9). Prmt4, along with the Mef2C protein, were localized
the muscle creatine kinase promoter in differentiating cell cul-
tures by ChIP, and inhibition of Prmt4 expression blocked the
expression of myogenic genes. The fact that Prmt4 was found
in a complex with Brg1 that promoted estrogen receptor-stim-
ulated gene expression (53) raises the possibility that both
PRMTs can cooperate with SWI/SNF chromatin remodeling
enzymes during gene activation events. However, the ATPase
activity of Brg1 was required for Prmt4 histone methylation in
vitro (53), whereas our data indicate that Prmt5 was necessary
for Brg1 association with the myogenin promoter and subse-
quent changes in promoter chromatin accessibility. Thus, the
mechanisms by which these two PRMTs function may differ.
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Furthermore, Prmt4 and Prmt5 do not share the same histone
substrates so far as is known. Whether Prmt5 and Prmt4 can
work synergistically to modify histones at the same myogenic
loci remains to be determined.
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